| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ... science 316 (5827), 1039-1043, 2007 | 4316 | 2007 |
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 1995 | 2014 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 1929 | 2010 |
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer F Cappuzzo, FR Hirsch, E Rossi, S Bartolini, GL Ceresoli, L Bemis, ... Journal of the National Cancer Institute 97 (9), 643-655, 2005 | 1814 | 2005 |
| Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A Szczésna, E Juhász, ... The lancet oncology 11 (6), 521-529, 2010 | 1395 | 2010 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The Lancet Oncology 16 (3), 257-265, 2015 | 1023 | 2015 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104, 2012 | 845 | 2012 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 766 | 2010 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 765 | 2014 |
| Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... New England Journal of Medicine 378 (24), 2288-2301, 2018 | 559 | 2018 |
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ... Science translational medicine 3 (99), 99ra86-99ra86, 2011 | 478 | 2011 |
| Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients F Cappuzzo, A Marchetti, M Skokan, E Rossi, S Gajapathy, L Felicioni, ... Journal of Clinical Oncology 27 (10), 1667, 2009 | 447 | 2009 |
| Akt phosphorylation and gefitinib efficacy in patients with advanced non–small-cell lung cancer F Cappuzzo, E Magrini, GL Ceresoli, S Bartolini, E Rossi, V Ludovini, ... Journal of the National Cancer Institute 96 (15), 1133-1141, 2004 | 435 | 2004 |
| Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients F Cappuzzo, M Varella-Garcia, H Shigematsu, I Domenichini, S Bartolini, ... J Clin Oncol 23 (22), 5007-18, 2005 | 422 | 2005 |
| Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial GL Ceresoli, F Cappuzzo, V Gregorc, S Bartolini, L Crino, E Villa Annals of Oncology 15 (7), 1042-1047, 2004 | 385 | 2004 |
| PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients A D'incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, ... British journal of cancer 112 (1), 95, 2015 | 380 | 2015 |
| Identifying and targeting ROS1 gene fusions in non–small cell lung cancer KD Davies, AT Le, MF Theodoro, MC Skokan, DL Aisner, EM Berge, ... Clinical Cancer Research 18 (17), 4570-4579, 2012 | 347 | 2012 |
| Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib FR Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy, L Bemis, AC Xavier, ... Annals of Oncology 18 (4), 752-760, 2007 | 330 | 2007 |
| Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma WD Travis, K Garg, WA Franklin, II Wistuba, B Sabloff, M Noguchi, ... Journal of clinical oncology 23 (14), 3279-3287, 2005 | 309 | 2005 |
| EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients F Cappuzzo, G Finocchiaro, E Rossi, PA Jänne, C Carnaghi, C Calandri, ... Annals of Oncology 19 (4), 717-723, 2007 | 298 | 2007 |
Romano DanesiProfessor of Pharmacology, University of PisaDirección de correo verificada de unipi.it
